New clinical trial studies a new drug for mesothelin-positive lung cancer
Raffit Hassan, M.D., Co-Chief of the Thoracic and Gastrointestinal Oncology Branch, is leading a new phase II clinical trial to test whether a new drug, anetumab ravtansine, can shrink tumors in mesothelin-positive lung cancer. Mesothelin is a protein found on the surface of many types of tumors, including most lung cancers, and this drug has been shown to kill cancer cells that have mesothelin on their surface. This trial aims to find a safe dose of the study drug for patients with lung cancer. For more information about this trial, please visit: https://ccr.cancer.gov/thoracic-and-gastrointestinal-oncology-branch/raffit-hassan.
To search all CCR clinical trials, please visit: https://ccr.cancer.gov/clinical-trials.Summary Posted: Thu, 06/01/2017